House Compounding Bill Would Regulate “Outsourcing Facilities” With Volume Limits
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps. Griffith, DeGette, and Green co-sponsor bill to improve FDA oversight of compounding with some provisions similar to Senate bill, possibly opening door to compromise.
You may also be interested in...
Track-and-Trace Bill Clears House With New Electronic Labeling Language
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.